Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia

Medical Section pf the American Lung Association: Guidelines for the Initial Management of Adults with Community-acquired Pneumonia: Diagnosis, Assessment of Severity, and Initial Antimicrobial Therapy

1993 • 1,063 citations

New and Emerging Etiologies for Community-Acquired Pneumonia with Implications for Therapy

1990 • 897 citations

The Effect of Prescribed Daily Dose Frequency on Patient Medication Compliance

1990 • 788 citations

Severe Community-acquired Pneumonia: Etiology, Prognosis, and Treatment

1990 • 336 citations

Microbial Etiology of Acute Pneumonia in Hospitalized Patients

1992 • 262 citations

Hospitalization decision in patients with community-acquired pneumonia: A prospective cohort study

1990 • 232 citations

Differential selection of multidrug efflux systems by quinolones in Pseudomonas aeruginosa

1997 • 178 citations

The aetiology, management and outcome of severe community-acquired pneumonia on the intensive care unit

1992 • 143 citations

Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro

1996 • 136 citations

In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria

1993 • 134 citations

In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone

1993 • 125 citations

Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins, and stability to hydrolysis by β-lactamases

1995 • 119 citations

The in-vitro activity of CP 99, 219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents

1995 • 82 citations

Quinolone Activity Against Anaerobes

1999 • 72 citations

Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia

1996 • 68 citations

Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin

1997 • 66 citations

Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219)

1996 • 53 citations

Evaluation of CP-99,219, a new fluoroquinolone, for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis

1995 • 48 citations

Trovafloxacin in treatment of rabbits with experimental meningitis caused by high-level penicillin-resistant Streptococcus pneumoniae

1997 • 46 citations

In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial

1994 • 41 citations

Investigation and Management of Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease

1993 • 40 citations

Effect of trovafloxacin, a new fluoroquinolone antibiotic, on the steady-state pharmacokinetics of theophylline in healthy volunteers

1997 • 38 citations

In vitro activity of trovafloxacin against Chlamydia pneumoniae

1997 • 34 citations

Quinolone Activity against Anaerobes

1995 • 32 citations

Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin

1998 • 22 citations

Epidemiology of Lower Respiratory Tract Infections

1995 • 21 citations

Diagnosis and antibiotic treatment of community-acquired pneumonia.

1991 • 19 citations

Antibacterial Therapy for Lower Respiratory Tract Infections in Adults: A Review

1992 • 18 citations